Systematic review and network meta‐analysis: Comparative effectiveness of therapies for second‐line <i>Helicobacter pylori</i> eradication

Yeo, Yee Hui; Hsu, Chia-Chen; Lee, Chiao-Chin; Ho, H.P.; Lin, Jaw–Town; Wu, Ming–Shiang; Liou, Jyh–Ming; Wu, Chang Chin; Disease, Taiwan Gastrointestinal

doi:10.1111/jgh.14462

Cited by 32 publications

(33 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this study, we considered treatment options for the management of H pylori infection recommended by the Maastricht V/Florence Consensus Report (by European Helicobacter pylori Study Group) and national guidelines for Croatia (by Croatian Gastroenterology Association), Slovenia (by Slovenian Association for Gastroenterology and Hepatology on the management of patients infected with H pylori), Italy (guidelines are endorsed by the Italian Society of Gastroenterology and the Italian Society of Digestive Endoscopy) and the UK (by The National Institute for Health and Care Excellence (NICE)) for adults. 11,[18][19][20][21][22][23][24] Maastricht V/ Florence Consensus Report proposes treatment duration of 14 days, unless 10-day therapies are proven effective locally. 11 For the purpose of the study, with reference to Maastricht V/ Florence Consensus Report, shortest recommended treatment duration of 10 days and longest recommended treatment duration of 14 days were considered.…”

Section: Methodsmentioning

confidence: 99%

Correlation of registered drug packs with Maastricht V/Florence Consensus Report and national treatment guidelines for management of Helicobacter pylori infection

Jukic

Rušić

Vuković

et al. 2019

Basic Clin Pharma Tox

View full text Add to dashboard Cite

High prevalence of Helicobacter pylori infection, the complexity for its treatment, poor correlation of registered drug packs or poor patient adherence to the treatment may contribute to antibiotic resistance and healthcare costs. The aim of the present study was to investigate whether registered drug packs are in accordance with European and national guidelines for H pylori eradication with reference to the number of drug units. In this study, we considered treatment options for the management of H pylori infection recommended by the Maastricht V/Florence Consensus Report and by national guidelines in the United Kingdom (UK), Croatia, Italy and Slovenia for adults. Drugs proposed by the guidelines were identified in national drug databases in July of 2019. When considering correlation for 10‐day treatment regimens, drug packs registered in Croatia could not be matched with recommendations for sequential therapies. A number of proposed treatments could not be matched due to small variety of drug packs in Croatia. Drug packs registered in the UK more often matched recommended 14‐day treatment regimens and national guidelines. With reference to European guidelines, 10‐day treatments could more frequently be matched in Italy and in Slovenia. Furthermore, results of this study indicate that there is smaller variety in drug pack sizes registered in Croatia and Slovenia when compared to UK and Italy. Considering poor correlation of drug packs with treatment guidelines for H pylori, adherence to antimicrobial treatment and proper disposal of antimicrobials is warrant. Discussing adherence to antimicrobial treatment with patients should be introduced as a standard of patient care and education.

show abstract

Section: Methodsmentioning

confidence: 99%

Correlation of registered drug packs with Maastricht V/Florence Consensus Report and national treatment guidelines for management of Helicobacter pylori infection

Jukic

Rušić

Vuković

et al. 2019

Basic Clin Pharma Tox

View full text Add to dashboard Cite

show abstract

“…Hits from virtual screening were shortlisted on the basis of binding energy based Vina empirical scoring function using À 8 kcal mol À 1 as the threshold [25]. In this regard, 46, [50] and 35 compounds were shortlisted against 3CL-protease, RdRp and helicase, respectively and were downloaded from the ZINC database [26]. In parallel, 62 FDA approved antiviral drugs with random targets were selected and their structure files were obtained from DrugBank in the SDF file format [27].…”

Section: Virtual Screening Of Fda Approved Antivirals and Drug-like Cmentioning

confidence: 99%

Identification of potential inhibitors of three key enzymes of SARS-CoV2 using computational approach

Iftikhar

Ali

Farooq

et al. 2020

Computers in Biology and Medicine

View full text Add to dashboard Cite

The recent outbreak of coronavirus disease-19 (COVID-19) continues to drastically affect healthcare throughout the world. To date, no approved treatment regimen or vaccine is available to effectively attenuate or prevent the infection. Therefore, collective and multidisciplinary efforts are needed to identify new therapeutics or to explore effectiveness of existing drugs and drug-like small molecules against SARS-CoV-2 for lead identification and repurposing prospects. This study addresses the identification of small molecules that specifically bind to any of the three essential proteins (RdRp, 3CL-protease and helicase) of SARS-CoV-2. By applying computational approaches we screened a library of 4574 compounds also containing FDA-approved drugs against these viral proteins. Shortlisted hits from initial screening were subjected to iterative docking with the respective proteins. Ranking score on the basis of binding energy, clustering score, shape complementarity and functional significance of the binding pocket was applied to identify the binding compounds. Finally, to minimize chances of false positives, we performed docking of the identified molecules with 100 irrelevant proteins of diverse classes thereby ruling out the non-specific binding. Three FDA-approved drugs showed binding to 3CL-protease either at the catalytic pocket or at an allosteric site related to functionally important dimer formation. A drug-like molecule showed binding to RdRp in its catalytic pocket blocking the key catalytic residues. Two other druglike molecules showed specific interactions with helicase at a key domain involved in catalysis. This study provides lead drugs or drug-like molecules for further in vitro and clinical investigation for drug repurposing and new drug development prospects.

show abstract

“…BQT is effective in areas, like Greece, where there is increasing dual clarithromycin and metronidazole resistance, which has been shown to impact all non-bismuth quadruple therapies (sequential, concomitant, or hybrid therapy) [127,131,159,160]. This regimen is independent of clarithromycin resistance, while metronidazole resistance has limited clinical impact, especially after prolongation of treatment (14 days) and an increase in the dose of metronidazole (1500 mg per day) [152,161]. As mentioned above, bismuth salts and tetracycline have not been available on the Greek market for many years and recent nationwide data are lacking.…”

Section: Recommendation Grade: B; Evidence Level: 2b; Agreement Levelmentioning

confidence: 99%

Hellenic consensus on Helicobacter pylori infection

Georgopoulos

Michopoulos

Rokkas³

et al. 2020

aog

View full text Add to dashboard Cite

The Hellenic Society of Gastroenterology recently organized the "Hellenic consensus on Helicobacter pylori (H. pylori) infection". The aim of this publication is to report the guidelines in order to aid the national gastroenterology community in the management of H. pylori infection. Forty-one delegates from all Greek regions, including gastroenterologists, pathologists, clinical microbiologists, epidemiologists and basic scientists, were invited to this meeting. The participants were allocated to 1 of the 4 main topics of the meeting: i.e., H. pylori diagnosis and association with diseases; H. pylori and gastric cancer; H. pylori and extragastric associated disorders; and H. pylori treatment. The results of each subgroup were submitted to a final consensus vote that included all participants. Relevant data based on international and Greek publications were presented, and the quality of evidence, strength of recommendation, and level of consensus were graded. The cutoff level of 70% was considered as acceptance for the final statement. It is hoped that the recommendations and conclusions of this report will guide Greek doctors in their daily practice concerning the management of H. pylori infection.

show abstract

Systematic review and network meta‐analysis: Comparative effectiveness of therapies for second‐line Helicobacter pylori eradication

Abstract: Quinolone-based bismuth-containing quadruple therapies for 10 days or more are the optimum second-line regimens for H. pylori eradication.

Cited by 32 publications

References 45 publications

Correlation of registered drug packs with Maastricht V/Florence Consensus Report and national treatment guidelines for management of Helicobacter pylori infection

Correlation of registered drug packs with Maastricht V/Florence Consensus Report and national treatment guidelines for management of Helicobacter pylori infection

Identification of potential inhibitors of three key enzymes of SARS-CoV2 using computational approach

Hellenic consensus on Helicobacter pylori infection

Contact Info

Product

Resources

About